Dataset Information

Inactivating mutations in NPC1L1 and protection from coronary heart disease.

ABSTRACT: Ezetimibe lowers plasma levels of low-density lipoprotein (LDL) cholesterol by inhibiting the activity of the Niemann-Pick C1-like 1 (NPC1L1) protein. However, whether such inhibition reduces the risk of coronary heart disease is not known. Human mutations that inactivate a gene encoding a drug target can mimic the action of an inhibitory drug and thus can be used to infer potential effects of that drug.We sequenced the exons of NPC1L1 in 7364 patients with coronary heart disease and in 14,728 controls without such disease who were of European, African, or South Asian ancestry. We identified carriers of inactivating mutations (nonsense, splice-site, or frameshift mutations). In addition, we genotyped a specific inactivating mutation (p.Arg406X) in 22,590 patients with coronary heart disease and in 68,412 controls. We tested the association between the presence of an inactivating mutation and both plasma lipid levels and the risk of coronary heart disease.With sequencing, we identified 15 distinct NPC1L1 inactivating mutations; approximately 1 in every 650 persons was a heterozygous carrier for 1 of these mutations. Heterozygous carriers of NPC1L1 inactivating mutations had a mean LDL cholesterol level that was 12 mg per deciliter (0.31 mmol per liter) lower than that in noncarriers (P=0.04). Carrier status was associated with a relative reduction of 53% in the risk of coronary heart disease (odds ratio for carriers, 0.47; 95% confidence interval, 0.25 to 0.87; P=0.008). In total, only 11 of 29,954 patients with coronary heart disease had an inactivating mutation (carrier frequency, 0.04%) in contrast to 71 of 83,140 controls (carrier frequency, 0.09%).Naturally occurring mutations that disrupt NPC1L1 function were found to be associated with reduced plasma LDL cholesterol levels and a reduced risk of coronary heart disease. (Funded by the National Institutes of Health and others.).

SUBMITTER: Myocardial Infarction Genetics Consortium Investigators

PROVIDER: S-EPMC4335708 | biostudies-literature | 2014 Nov

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Inactivating mutations in NPC1L1 and protection from coronary heart disease.

Stitziel Nathan O NO Won Hong-Hee HH Morrison Alanna C AC Peloso Gina M GM Do Ron R Lange Leslie A LA Fontanillas Pierre P Gupta Namrata N Duga Stefano S Goel Anuj A Farrall Martin M Saleheen Danish D Ferrario Paola P König Inke I Asselta Rosanna R Merlini Piera A PA Marziliano Nicola N Notarangelo Maria Francesca MF Schick Ursula U Auer Paul P Assimes Themistocles L TL Reilly Muredach M Wilensky Robert R Rader Daniel J DJ Hovingh G Kees GK Meitinger Thomas T Kessler Thorsten T Kastrati Adnan A Laugwitz Karl-Ludwig KL Siscovick David D Rotter Jerome I JI Hazen Stanely L SL Tracy Russell R Cresci Sharon S Spertus John J Jackson Rebecca R Schwartz Stephen M SM Natarajan Pradeep P Crosby Jacy J Muzny Donna D Ballantyne Christie C Rich Stephen S SS O'Donnell Christopher J CJ Abecasis Goncalo G Sunaev Shamil S Nickerson Deborah A DA Buring Julie E JE Ridker Paul M PM Chasman Daniel I DI Austin Erin E Kullo Iftikhar J IJ Weeke Peter E PE Shaffer Christian M CM Bastarache Lisa A LA Denny Joshua C JC Roden Dan M DM Palmer Colin C Deloukas Panos P Lin Dan-Yu DY Tang Zheng-zheng ZZ Erdmann Jeanette J Schunkert Heribert H Danesh John J Marrugat Jaume J Elosua Roberto R Ardissino Diego D McPherson Ruth R Watkins Hugh H Reiner Alex P AP Wilson James G JG Altshuler David D Gibbs Richard A RA Lander Eric S ES Boerwinkle Eric E Gabriel Stacey S Kathiresan Sekar S

The New England journal of medicine 20141112 22

<h4>Background</h4>Ezetimibe lowers plasma levels of low-density lipoprotein (LDL) cholesterol by inhibiting the activity of the Niemann-Pick C1-like 1 (NPC1L1) protein. However, whether such inhibition reduces the risk of coronary heart disease is not known. Human mutations that inactivate a gene encoding a drug target can mimic the action of an inhibitory drug and thus can be used to infer potential effects of that drug.<h4>Methods</h4>We sequenced the exons of NPC1L1 in 7364 patients with cor ...[more]

PMID: 25390462

Similar Datasets

Project description:Higher-than-normal levels of circulating triglycerides are a risk factor for ischemic cardiovascular disease. Activation of lipoprotein lipase, an enzyme that is inhibited by angiopoietin-like 4 (ANGPTL4), has been shown to reduce levels of circulating triglycerides.We sequenced the exons of ANGPTL4 in samples obtain from 42,930 participants of predominantly European ancestry in the DiscovEHR human genetics study. We performed tests of association between lipid levels and the missense E40K variant (which has been associated with reduced plasma triglyceride levels) and other inactivating mutations. We then tested for associations between coronary artery disease and the E40K variant and other inactivating mutations in 10,552 participants with coronary artery disease and 29,223 controls. We also tested the effect of a human monoclonal antibody against ANGPTL4 on lipid levels in mice and monkeys.We identified 1661 heterozygotes and 17 homozygotes for the E40K variant and 75 participants who had 13 other monoallelic inactivating mutations in ANGPTL4. The levels of triglycerides were 13% lower and the levels of high-density lipoprotein (HDL) cholesterol were 7% higher among carriers of the E40K variant than among noncarriers. Carriers of the E40K variant were also significantly less likely than noncarriers to have coronary artery disease (odds ratio, 0.81; 95% confidence interval, 0.70 to 0.92; P=0.002). K40 homozygotes had markedly lower levels of triglycerides and higher levels of HDL cholesterol than did heterozygotes. Carriers of other inactivating mutations also had lower triglyceride levels and higher HDL cholesterol levels and were less likely to have coronary artery disease than were noncarriers. Monoclonal antibody inhibition of Angptl4 in mice and monkeys reduced triglyceride levels.Carriers of E40K and other inactivating mutations in ANGPTL4 had lower levels of triglycerides and a lower risk of coronary artery disease than did noncarriers. The inhibition of Angptl4 in mice and monkeys also resulted in corresponding reductions in these values. (Funded by Regeneron Pharmaceuticals.).

Dataset Information

Inactivating mutations in NPC1L1 and protection from coronary heart disease.

Publications

Inactivating mutations in NPC1L1 and protection from coronary heart disease.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets